

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 March 2025 (27.03.2025)



(10) International Publication Number
WO 2025/064741 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/04 (2006.01)
A61K 39/395 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2024/047585

(22) International Filing Date:

20 September 2024 (20.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/584,480	21 September 2023 (21.09.2023)	US
63/620,610	12 January 2024 (12.01.2024)	US
63/650,806	22 May 2024 (22.05.2024)	US
63/672,135	16 July 2024 (16.07.2024)	US
63/694,044	12 September 2024 (12.09.2024)	US

(71) Applicants: **AGENSYS, INC.** [US/US]; 2375 Water-view Drive, Northbrook, IL 60062 (US). **SEAGEN INC.** [US/US]; 21823 30th Drive S.E., Bothell, WA 98021 (US). **MERCK SHARP & DOHME LLC** [US/US]; 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065 (US).

(72) Inventor: **ABIDOYE, Oyewale, O.**; 21823 30th Drive S.E., Bothell, WA 98021 (US).

(74) Agent: **LIANG, Bing** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: TREATING LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WITH ANTI-191P4D12 ANTI-BODY DRUG CONJUGATES IN COMBINATION WITH PEMBROLIZUMAB




FIG. 7

(57) Abstract: Provided herein are methods for treating cisplatin eligible and ineligible patients with unresectable locally advanced or metastatic urothelial cancer with antibody drug conjugates (ADC) that bind to 191P4D12 proteins in combination with pembrolizumab, wherein the anti-191P4D12 antibody is conjugated to one or more units of monomethyl auristatin E (MMAE).

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*